Suggested remit: To appraise the clinical and cost effectiveness of belumosudil within its marketing authorisation for treating chronic graft versus host disease after 2 or more therapies.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
|
Further information
|
Invitation to participate
|
| Process |
STA Standard
|
| ID number |
4021
|
Provisional Schedule
| Expected publication |
22 November 2023 |
Project Team
Email enquiries
| External Assessment Group |
BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors |
Sanofi (belumosudil) |
| Others |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Anthony Nolan |
| Professional groups |
Neonatal and Paediatric Pharmacists Group |
| |
Royal College of Physicians |
| Comparator companies |
Novartis Pharmaceuticals UK (mycophenolate mofetil) |
| |
Mallinckrodt Pharmaceuticals |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
National Institute for Health Research |
|
Date
|
Update
|
|
13 September 2023
|
Committee meeting |
|
13 January 2023
|
Invitation to participate |
|
13 January 2023
|
In progress |
|
06 January 2023
|
Topic selection |
|
06 January 2023
|
Topic selection. The topic routing was discussed at the Topic Selection Oversight Panel (TSOP) in November 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Please see project documents for further details. The evaluation is expected to begin with an invitation to participate in January 2023 with a first committee meeting in September 2023. |
|
07 November 2022 (14:00)
|
Scoping workshop |
|
09 September 2022 - 07 October 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4021 |
|
09 September 2022
|
In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual